ENGLISH ABSTRACT
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[Cancer and venous thromboembolism].

Cancer and venous thrombo-embolism is a frequent clinical association. Tumour cells activate the coagulation cascade. Surgery, chemotherapy and antiangiogenic agents are also associated with an increased risk of thrombosis. Current evidence does not suggest that a systematic screening for cancer after an unexplained thrombosis is associated with a clinical benefit. Risk factors for thrombosis specific to the cancer population have been identified. Recent studies suggest that prophylactic treatment may reduce the incidence of venous thrombo-embolism in patients with cancer. These results need to be confirmed. Treatment of venous thrombo-embolism in cancer patients is primarily based on low-molecular weight heparin administered for 3 or 6 months. Experimental data suggest that low-molecular weight heparin may also increase the survival of patients with cancer through a direct effect on tumour biology. Several clinical trials are underway to confirm this hypothesis.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app